Methicillin-Resistant Staphylococcus Aureus (MRSA) Testing Market Growth Forecast Through 2030: Market Size And Trends In 2026
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Methicillin-Resistant Staphylococcus Aureus (MRSA) Testing Market Growth From $4.18 Billion In 2026 To $5.28 Billion By 2030 At A CAGR Of 6%
The methicillin-resistant staphylococcus aureus (MRSA) testing market has seen robust expansion in recent years. It is anticipated to increase from $3.95 billion in 2025 to $4.18 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.8%. The growth observed in the preceding period can be linked to the escalating prevalence of hospital-acquired infections, a heightened awareness of antibiotic resistance, the expansion of diagnostic laboratory infrastructure, the advancement of hospital infection control programs, and the rising adoption of culture-based diagnostic methods.
The methicillin-resistant staphylococcus aureus (MRSA) testing market is projected to experience substantial growth over the coming years, with its size forecast to reach $5.28 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.0%. This expansion is primarily driven by factors such as the increasing integration of rapid molecular diagnostic technologies, heightened investment in precision medicine and pathogen genomics, the broadening of automated laboratory systems, a rising need for real-time infection surveillance, and a more stringent regulatory emphasis on antimicrobial resistance control. Additionally, notable trends for this period encompass the escalating embrace of rapid molecular diagnostics for detecting antibiotic resistance, the expanding deployment of point-of-care MRSA testing within hospital settings, the widespread adoption of automated microbiology workflows in diagnostic labs, the growth of infection surveillance initiatives across healthcare facilities, and a rising requirement for multiplex assays in screening for hospital-acquired infections.
Get A Free Sample Report With In-Depth Market Insights:
Methicillin-Resistant Staphylococcus Aureus (MRSA) Testing Market Expansion Drivers: What’s Shaping Future Growth?
The rising occurrence of hospital-acquired infections is anticipated to boost expansion in the methicillin-resistant staphylococcus aureus (MRSA) testing market in the future. HAIs, or hospital-acquired infections, refer to secondary infections developed by patients during medical or surgical care in a healthcare setting. This global increase is due to the growing complexity of medical procedures and a large number of immunocompromised patients, which provides more chances for opportunistic pathogens to establish themselves. MRSA testing aids in managing these infections by enabling healthcare professionals to promptly identify colonized individuals and put isolation measures in place to stop widespread transmission within facilities. For example, the Health Security Agency, a national executive agency based in the UK, reported that in August 2025, total MRSA bacteremia cases hit 81, an 8.0% rise from 75 cases recorded in August 2024. Consequently, the growing incidence of hospital-acquired infections is projected to stimulate expansion within the methicillin-resistant staphylococcus aureus (MRSA) testing market.
Methicillin-Resistant Staphylococcus Aureus (MRSA) Testing Market Segment Analysis: What Are The Core Market Categories?
The methicillin-resistant staphylococcus aureus (mrsa) testing market covered in this report is segmented –
1) By Type: Healthcare Acquired Methicillin Resistant Staphylococcus Aureus, Community Acquired Methicillin Resistant Staphylococcus Aureus, Hospital Acquired Methicillin Resistant Staphylococcus Aureus
2) By Indication: Skin And Soft Tissue Infections (SSTIs), Pneumonia, Bloodstream Infections, Surgical And Medical Infections, Other Indications
3) By Technology: Polymerase Chain Reaction (PCR), Real Time Polymerase Chain Reaction (RT-PCR), Chromogenic Media, Enzyme Linked Immunosorbent Assay (ELISA), Other Technologies
4) By End User: Hospitals, Diagnostic Laboratories, Research Institutes, Ambulatory Care Centers, Other End Users
Subsegments:
1) By Healthcare Acquired Methicillin Resistant Staphylococcus Aureus: Intensive Care Unit Associated Infections, Catheter Related Infections, Ventilator Associated Infections, Post Surgical Site Infections, Long Term Care Facility Infections
2) By Community Acquired Methicillin Resistant Staphylococcus Aureus: Skin And Soft Tissue Infections, Athlete Associated Infections, Household Transmission Infections, Community Cluster Infections, School And Daycare Associated Infections
3) By Hospital Acquired Methicillin Resistant Staphylococcus Aureus: Surgical Site Infections, Bloodstream Infections, Respiratory Tract Infections, Device Associated Infections, Wound And Burn Infections
Methicillin-Resistant Staphylococcus Aureus (MRSA) Testing Market Strategic Trends: What Defines The Next Growth Phase?
Key players in the methicillin-resistant staphylococcus aureus (MRSA) testing market are concentrating on incorporating artificial intelligence into their testing procedures, particularly through AI-powered imaging analysis, to secure a competitive advantage. This AI-powered imaging analysis leverages artificial intelligence algorithms to automatically and accurately interpret bacterial growth patterns on chromogenic media plates within MRSA screening workflows. As an illustration, in May 2023, Becton, Dickinson and Company (BD), a US-based medical technology firm, received FDA 510(k) clearance for its BD Kiestra MRSA Imaging application. This application automates the inspection of Petri dishes for mauve-colored MRSA colonies, allows for the batch review of negative results, and integrates with BD Synapsys Informatics for streamlined worklist organization. Laboratories consequently experience advantages like shortened turnaround times, reduced labor demands, and the capacity to redeploy staff to more intricate analyses.
Methicillin-Resistant Staphylococcus Aureus (MRSA) Testing Market Leading Companies And Competitive Benchmarking
Major companies operating in the methicillin-resistant staphylococcus aureus (mrsa) testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, bioMérieux SA, Hologic Inc., QuidelOrtho Corporation, Bruker Corporation, Bio-Rad Laboratories Inc., QIAGEN N. V., Randox Laboratories Ltd., SD Biosensor Inc., Seegene Inc., Hardy Diagnostics Inc., Alifax S. r. l., Ganesh Diagnostic and Imaging Centre Pvt. Ltd., Uniogen Oy, 3B BlackBio Dx Limited, Orange Health Labs Private Limited
View The Full Methicillin-Resistant Staphylococcus Aureus (MRSA) Testing Market Report:
Methicillin-Resistant Staphylococcus Aureus (MRSA) Testing Market Largest Region By Revenue And Market Share
North America was the largest region in the methicillin-resistant staphylococcus aureus (MRSA) testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the methicillin-resistant staphylococcus aureus (MRSA) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
